Get started
Author

Satoshi Yokoyama

ORCID: 0000-0003-3031-6287
Observed ORCID: 0000-0003-3031-6287
OpenAlex ID: A5069018853
Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprim‐sulfamethoxazole without changes in glomerular filtration rate
2022 · Satoshi Yokoyama, Junichi Nakagawa, et al. · Journal of Clinical Pharmacy and Therapeutics · 13
Impact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers
2023 · Satoshi Yokoyama, Junichi Nakagawa, et al. · Pharmacology Research & Perspectives · 5
PDF
Quantification of the Plasma Concentration of Vadadustat by High-Performance Liquid Chromatography with Ultraviolet Detection and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
2024 · Satoshi Yokoyama, Junichi Nakagawa, et al. · Therapeutic Drug Monitoring · 4
Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report
2024 · Junichi Nakagawa, Keinosuke Ishido, et al. · Journal of Pharmaceutical Health Care and Sciences · 3
PDF
Data Mining of the FDA Adverse Event Reporting System and Animal Experiments for Assessment of Rhabdomyolysis Risk Associated with Lipid-lowering Drugs
2025 · Shinji Kobuchi, Daisuke Sugiyama, et al. · International Journal of Medical Sciences · 1
PDF
Marked supratherapeutic anticoagulation following S-1 therapy despite low-dose warfarin in a postgastrectomy Japanese patient: a case report highlighting sequential pharmacokinetic and pharmacodynamic risk factors
2026 · Satoshi Yokoyama, Takahiro Muroya, et al. · Research Square
PDF
Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics
2026 · Satoshi Yokoyama, Michiko Shimada, et al. · European Journal of Drug Metabolism and Pharmacokinetics
Works count: 7
Citation count: 26
H-index: 3
I10-index: 1
Year
Topic
Type